

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	1	of	10

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)				
KH	AA	US1974/3823135	07-09-1974	Pilgram et al.		
	AB	US1996/5512549	04-30-1996	Chen et al.		
	AC	US1996/5580979	12-03-1996	Bachovchin		
	AD	US1997/5614492	03-25-1997	Habener		
	AE	US2000/6156739	12-5-2000	Griffin et al.		
	AF	US2000/6166063	12-26-2000	Vilhauer		
	AG	US2001/6258597-B1	07-10-2001	Bachovchin		
	AH	US2001/0020008-A1	09-06-2001	Demuth et al.		
	AI	US2001/6303661-B1	10-16-2001	Demuth et al.		
	AJ	US2001/6319893-B1	11-20-2001	Demuth et al.		
	AK	US2001/0051648-A1	12-13-2001	Demuth et al.		
	AL	US2002/0049153-A1	04-25-2002	Bridon et al.		
	AM	US2002/0049164-A1	04-25-2002	Demuth et al.		
	AN	US2002/6380398-B2	04-30-2002	Kanstrup et al.		
	AO	US2002/0082427-A1	06-27-2002	Demuth et al.		
	AP	US2002/6448045-B1	09-10-2002	Levine et al.		
	AQ	US2002/0198242-A1	12-26-2002	Demuth et al.		
	AR	US2002/0198380-A1	12-26-2002	Belzer et al.		
	AS	US2002/6500804-B2	12-31-2002	Demuth et al.		
	AT	US2003/0008925-A1	01-09-2003	Demuth et al.		
	AU	US2003/6548481-B1	04-15-2003	Demuth et al.		
	AV	US2003/0092630-A2	05-15-2003	Demuth et al.		
	AW	US2003/0119750-A1	06-26-2003	Demuth et al.		
	AX	US2003/0130199-A1	07-10-2003	von Hoersten et al.		
	AY	US2003/0134802-A1	07-17-2003	Demuth et al.		
	AZ	US2003/0135023-A1	07-17-2003	Demuth et al.		
	BA	US2003/0148961-A1	08-07-2003	Heiser et al.		
	BB	US2003/0153509-A1	08-14-2003	Bachovchin et al.		
	BC	US2003/0162820-A1	08-28-2003	Demuth et al.		
	BD	US2003/0166578-A1	09-04-2003	Arch et al.		
	BE	US2003/6620910-B1	09-16-2003	Calas et al.		
	BF	US2003/0176357-A1	09-18-2003	Pospisilik et al.		
	BG	US2003/0199451-A1	10-23-2003	Mogensen et al.		
	BH	US2003/0199672-A1	10-23-2003	Knudsen et al.		

Examiner Signature	<i>A. My Ph</i>	Date Considered	10/19/2006
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,638
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C3

<input checked="" type="checkbox"/>	BI	US2003/0236272-A1	12-25-2003	Richard David Carr	
<input checked="" type="checkbox"/>	BJ	US2004/6703238-B2	03-09-2004	Bachovchin	
<input checked="" type="checkbox"/>	BK	US2004/0054171-A1	03-18-2004	Jensen et al.	
<input checked="" type="checkbox"/>	BL	US2004/0058876-A1	03-25-2004	Hoffmann et al.	
<input checked="" type="checkbox"/>	BM	US2004/0132732-A1	07-08-2004	Han et al.	
<input checked="" type="checkbox"/>	BN	US2004/0167191-A1	08-26-2004	Demuth et al.	
<input checked="" type="checkbox"/>	BO	US2004/0171555-A1	09-02-2004	Demuth et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
<input checked="" type="checkbox"/>	BP	FR 2.162.106 (English Abstract-1973)	11-30-1972	Amschler et al.		
<input checked="" type="checkbox"/>	BQ	WO 89/10701	11-16-1989	BASF		
<input checked="" type="checkbox"/>	BR	EP 0378255-A2	07-18-1990	Janssen Pharmaceutica		
<input checked="" type="checkbox"/>	BS	GB 2230527-A	10-24-1990	Imperial Chemical Industries Plc		
<input checked="" type="checkbox"/>	BT	WO 91/12001	08-22-1991	Merck & Co., Inc.		
<input checked="" type="checkbox"/>	BU	WO 83/21162	01-28-1993	Nissan Chemical Industries, Ltd.		
<input checked="" type="checkbox"/>	BV	WO 93/08259 (A2)	04-29-1993	New England Medical Center Hospitals, Inc.		
<input checked="" type="checkbox"/>	BW	WO 93/08259 (A3)	04-29-1993	New England Medical Center Hospitals, Inc.		
<input checked="" type="checkbox"/>	BX	EP 0547442-A1	06-23-1993	E.R. Squibb & Sons, Inc.		
<input checked="" type="checkbox"/>	BY	WO 94/03055	02-17-1994	U.S. Government, Secty. HHS		
<input checked="" type="checkbox"/>	BZ	EP 0587377-A2	03-16-1994	Eli Lilly and Company		
<input checked="" type="checkbox"/>	CA	WO 95/35031	12-28-1995	La Trobe University		
<input checked="" type="checkbox"/>	CB	WO 96/32384	10-17-1996	Taiho Pharmaceutical Co., Ltd.		
<input checked="" type="checkbox"/>	CC	WO 96/38550	12-05-1996	Dana-Farber Cancer Institute, Inc.		
<input checked="" type="checkbox"/>	CD	WO 97/40832	11-06-1997	Hans-Knoll-Institut Fur Naturstoff		
<input checked="" type="checkbox"/>	CE	JP 9295977	11-18-1997	Terumo Corp.		
<input checked="" type="checkbox"/>	CF	WO 98/00439	01-08-1998	Trustees of Tufts College		
<input checked="" type="checkbox"/>	CG	WO 98/24780	06-11-1998	Amgen Inc.		
<input checked="" type="checkbox"/>	CH	WO 99/16864	04-08-1999	Point Therapeutics, Inc.		
<input checked="" type="checkbox"/>	CI	WO 99/38501	08-05-1999	Trustees of Tufts University		

Examiner Signature	<i>A. M. Kim</i>	Date Considered	10/19/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	3	of	10

	CJ	WO 99/50249	10-07-1999	Du Pont Pharmaceuticals Company		
KK	CK	WO 99-61431	12-02-1999	Probiobrug		
	CL	WO 99/67278	12-29-1999	Pro-Biodrug		
	CM	WO 99/67279	12-29-1999	Pro-Biodrug		
	CN	WO 00/07617	02-17-2000	Novo Nordisk		
	CO	WO 00/09666	02-24-2000	U.S. Government, Secty. HHS		
	CP	WO 00/15211	03-23-2000	Akasis Pharmaceuticals, Inc.		
	CQ	WO 00/76988-A1	04-11-2000	Probiobrug		
	CR	WO 00/34241	06-15-2000	Novartis AG		
	CS	WO 00/47219	08-17-2000	Ontogeny, Inc.		
	CT	WO 00/53171	09-14-00	Molteni L. E. C. Del Fratelli Alitti Societa' Di Esercizio S.P.A.		
	CU	WO 00/57721	10-05-2000	Akasis Pharmaceuticals, Inc.		
	CV	WO 01/14318-A2	03-01-2001	Probiobrug		
	CW	WO 01/34594-A1	05-17-2001	Guilford Pharmaceuticals, Inc.		
	CX	WO 01/52825-A2	07-26-2001	Novartis AG		
	CY	WO 01/56988-A1	08-09-2001	Kirin Beer Kabushiki Kaisha		
	CZ	WO 01/70729-A1	09-27-2001	Sanofi-Synthelabo		
	DA	WO 01/97808-A1	12-27-2001	Smithkline Beecham PLC		
	DB	WO 02/34242-A2	05-02-2002	Probiobrug AG		
	DC	WO 02/34243-A2	05-02-2002	Probiobrug AG		
	DD	WO 02/083109-A1	10-24-2002	Ferring BV		
	DE	JP 2002/338466	11-27-2002	Tanabe Seiyaku Co Ltd		
	DF	WO 03/002593-A2	01-09-2003	Probiobrug AG		
	DG	WO 03/002595-A2	01-09-2003	Probiobrug AG		
	DH	WO 03/002596-A2	01-09-2003	Probiobrug AG		
	DI	WO 03/016335-A2	02-27-2003	Probiobrug AG		
	DJ	WO 03/022871-A2	03-20-2003	Probiobrug AG		
	DK	WO 03/026652-A1	04-03-2003	Bristol-Myers Squibb Company		
	DL	WO 03/030946-A1	04-17-2003	Novartis AG		
	DM	WO 03/033524-A2	04-24-2003	Probiobrug AG		
	DN	JP 2003/128551	05-08-2003	Sankyo Co LTD		
	DO	WO 03/040174-A2	05-15-2003	Probiobrug AG		
	DP	WO 03/045228-A2	06-05-2003	Trustees of Tufts College		
	DQ	WO 03/045977-A2	06-05-2003	Trustees of Tufts College		
	DR	WO 03/048081-A2	06-12-2003	Bristol-Myers Squibb Company		
	DS	WO 03/048158-A1	06-12-2003	Bristol-Myers Squibb Company		
	DT	WO 03/057200-A2	07-17-2003	Novo Nordisk		

Examiner Signature		Date Considered	10/19/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered/ whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	10/809,638
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	4	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C3

KH	DU	WO 03/063903-A2	08-07-2003	Probiobug AG		
	DV	WO 03/072556-A1	09-04-2003	Probiobug AG		
	DW	WO 03/082898-A2	10-09-2003	Probiobug AG		
	DX	WO 03/092605-A2	11-13-2003	Trustees of Tufts College		
	DY	WO 03/099279-A1	12-04-2003	Novartis AG		
	DZ	WO 03/099818-A1	12-04-2003	Chiron Corporation		
	EA	WO 03/106416-A2	12-24-2003	Smithkline Beecham Corporation		
	EB	WO 2004/017989-A1	03-04-2004	Probiobug AG		
	EC	JP 2004/99600-A	04-02-2004	Sankyo Co. Ltd.		
	ED	WO 2004/031374-A2	04-15-2004	Probiobug AG		
	EE	JP 2004/123738-A	04-22-2004	Takeda Chem Ind Ltd		
	EF	WO 2004/037176-A2	05-06-2004	Bristol-Myers Squibb Company		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	EG	ARGAUD, DORIANE et al., Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993).	
	EH	ASHCROFT, STEPHEN J.H. et al., Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1986), 89 pp. 469-472.	
	EI	BAL, GUNTHER, Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors, (2002) Universiteit Antwerpen.	
	EJ	BARAKAT, S.E.S., Synthesis and hypoglycemic activity of some new 3-[4-[[[(cyclohexylamino) carbonyl] amino]sulfonyl]phenyl]-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000), pp. 48-57.	
	EK	BARAKAT, S.E.S., Synthesis and Hypoglycemic Activity of Some New 4(3H)-Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 8, No.4 (2000) pp.195-204.	
	EL	BAKER, B.R. et al., Irreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydrofolic Reductase (1,2), Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48.	
	EM	BELGODERE, ELENA et al., Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9.	
	EN	BEZUGLYI, P.O. et al., Synthesis of arylsulfonyl hydrazide of 3-R-quinazolinone-4-carboxyl-2-acid, Pharmaceutical Journal (1979), pp. 70-71.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	5	of	10

KH	EO	BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazoline (Centipiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414.
	EP	BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 399-405.
	EQ	BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity in Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391.
	ER	BUCKLEY, DI, Analysis of the Degradation of Insulintropin (GLP-1 (7-37)) In Human Plasma and Production of Degradation Resistant Analogs.
	ES	CHATTERJEE, A.K. et al., Effect of Centipiperalone in Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008.
	ET	CHATTERJEE, A.K. et al., Effect of Centipiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1981) pp.270-272.
	EU	COPPOLA, GARY M. et al., 1-Aminomethylisoquinoline-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors, Bioorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558.
	EV	DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 <i>in Vitro</i> Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite <i>in Vivo</i> , Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957.
	EW	DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, Vol. 44 (1996), pp. 1125-1131.
	EX	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism in Vivo, Regulatory Peptides Vol. 64 Issues 1-3 (1996) p.30.
	EY	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig, Diabetes, Vol. 47 (1998), pp. 764-769.
	EZ	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4.
	FA	DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metaformin effects on depeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 296 (2002) pp. 229-232.
	FB	ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, Proc. Nat. Acad. Sci. Early Edition (2003), pp. 1-6.
	FC	FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and In Vivo, J. Clinical Endocrinology & Metabolism (1986), pp. 898-905.

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	6	of	10

KH	FD	GARRATT, PETER J. et al., A Novel Synthesis of Dihydropyrimidines, J. Chem. Soc., Chem. Commun. (1987), pp.568-569.	
	FE	GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Hydroxypyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, J. Org. Chem. (1988), pp. 1062-1069.	
	FF	GAZIT, AVIV et al., Typhostins IV - Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4- Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No.8 (1996) pp. 1203-1207.	
	FG	GUERRIERI, N., et al., Vanadium Inhibition of Serine and Cysteine Proteases, Comparative Biochemistry and Physiology Part A 122 (1997), pp.331-336.	
	FH	GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Triazepino- and Triazoclonquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395.	
	FI	GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, Nature, Vol. 223 (1969), p. 524.	
	FJ	GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene 5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido [1,2-a] pyrimidines, Indian Journal of Chemistry, Vol. 9 (1971), pp. 201-206.	
	FK	HERMECZ, ISTVAN et al., Pyrdo[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, Medicinal Research Reviews, Vol. 8, No. 2 (1988) pp.203-230.	
	FL	HINKE, SIMON A. et al., Metaformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochemical and Biophysical Research Communications, 291 (2002) pp. 1302-1308.	
	FM	HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metaformin and Dipeptidyl Peptidase IV Inhibitors, Diabetes Care, Vol. 25, No. 8 (2002) pp. 1490-1492.	
	FN	HOLZ, GEORGE G. et al, Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1(7-37), Nature, Vol. 361 (1993), pp. 362-365.	
	FO	KHALID, NORAINI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32, Applied and Environmental Microbiology (1990), pp. 381-388.	
	FP	KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependant Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV, Endocrinology, Vol. 136, No. 8 (1995) 3585-3596.	
	FQ	KIMURA, TOSHIKIRO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, Biological & Pharmaceutical Bulletin, Vol. 19, No. 8 (1996), 897-900.	
✓	FR	KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From <i>Prevotella loeschei</i> ATCC 15930, Archives of Oral Biology, 46 (2001), 759-766.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	7	of	10

KH	FS	KUSAR, MIHAEL et al., Diethyl N,N-Dimethylaminomethylenemalonate in the Synthesis of Fused Heterocyclic Systems, Heterocyclic Chem. 33 (1996) pp. 1041-1046.	
/	FT	LI JINPING, et al., Permolybdate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, Biochemistry, 34 (1995) 6218-6225.	
/	FU	LIN, JIAN, Total Synthesis and Biological Evaluation of Fluoroolefin-containing Dipeptidyl Isosteres as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1998).	
/	FV	LOESER, ERIC et al., Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, Synthetic Communications, 32(3) (2002) pp. 403-409.	
/	FW	MANNUCCI, EDUARDO, et al., Effect of Metformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects, Diabetes Care, Vol. 24, No. 3 (2001) 489-494.	
/	FX	MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum, Eur. J. Biochem, Vol. 214, 829-835 (1991).	
/	FY	MEYEROVITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, The Journal of Biological Chemistry, Vol. 262, No. 14 (1987) 6658-6662.	
/	FZ	MALLOY, J. ARDILL et al., Effect of Metformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, Diabetologia, Vol. 19 (1980) 93-96.	
/	GA	MUKERJEE, S.S. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm, Biochemical Pharmacology, Vol. 23 (1974) 3066-3067.	
/	GB	MUKERJEE, S.S. et al., Studies on the Mechanism of Centipiperalone-Induced Hypoglycemia, Acta Diabet. Lat 13, 8 (1976) p 8.	
/	GC	MUKERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centipiperalone in Rats & Rhesus Monkeys, Indian Journal of Experimental Biology, Vol. 17 (1979) pp. 1346-1349.	
/	GD	MUKERJEE, S.S. et al., Tissue Distribution of [³ H]Centipiperalone after Oral Administration, Indian J. Biochem. Biophys., Vol. 17 (1980) pp. 399-401.	
/	GE	MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, Biochemical Pharmacology, Vol. 22 (1972) pp. 1529-1531.	
/	GF	MUKHERJEE, SURATH K. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats, Biochemical Pharmacology, Vol. 22 (1973) pp. 2205-2206.	
✓	GG	MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, Ind. J. Physiol. & Allied Sci., Vol. 30, No. 3 (1976) pp. 105-118.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	8	of	10

KY	GH	MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycemic Agent A-4166 in Relation to Food, Diabetologia Vol. 38 A194 Supplement 1 (1995).	
	GI	MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centipernalone-Induced Hypoglycemia, Acta Diabet. Lat. 13, 8, (1976) pp. 8-19.	
	GJ	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V - Synthesis & Hypoglycemic Activity of Some New 1-[[p-(4-OXO-2-Methyl/Phenyl-3 (4H)-Quinazolyl) Phenyl]] 3-Aryl-2-Ureas, Indian Drugs, 25 (1) (1987) pp. 19-22.	
	GK	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[[p-(4-OXO-2-Substituted-3(4H)-Quinazolyl)-Phenyl] Sulphonyl]-3-Aryl/Cyclohexyl-2-Thioureas, Current Science, Vol. 56, No. 24 (1987) pp. 1263-1265.	
	GL	NAKAMURA, SEUI, et al., Effect of Chronic Vanadate Administration in Partially Depancreatized Rats, Diabetes Research and Clinical Practice 27 (1995) pp. 51-59. (Abstract Only)	
	GM	OHKUBO, I., et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, J. Biochem. (Tokyo) (1994) 116(5) pp. 1182-11826.	
	GN	PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, Pharmacological Research Communications, Vol. 17, No.8 (1985) pp. 699-709.	
	GO	PAULY, R.P. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) In Rat Results in Improved Glucose Tolerance, Regulatory Peptides Vol. 64, Issues 1-3 (1996) p. 148.	
	GP	PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolid, Diabetes, Vol. 47 (1998) pp.1253-1258.	
	GQ	PILLAI, SREEKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, The Journal of Biological Chemistry, Vol. 260, No. 14 (1985) pp. 8384-9.	
	GR	PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62. Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, J. Org. Chem. 51 (1985) 394-399.	
	GS	POJE, M. et al., Diabetogenic action of alloxan-like derivatives of uric acid, Experientia 36 (1980) pp. 78-9.	
	GT	POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of 5-Imino-2,4,6-(1H,3H,5H)-pyrimidinetrione Salts and Their Alloxan-like Covalent Adducts, J. Med. Chem. 26 (1983) 881-4.	
	GU	POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, Arzneim.-Forsch./ Drug Res. 28 (1978), 791-93.	
	GV	PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide1(7-36)amide in Dogs and is Degraded More Quickly in Vitro by Dog Plasma, European Journal of Drug Metabolism and Pharmacokinetics, Vol. 21 (1995), pp. 51-59.	

Examiner Signature	<i>Amy M</i>	Date Considered	10/19/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun Feng
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	SYR-DPP-IV-5004-C3
Sheet	9	of	10

KH	GW	RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Suitably Functionalized 3H-quinazolin-4-ones, Bioorganic & Medicinal Chemistry 11 (2003), pp. 2439-2444.	
	GX	SAWYER, JAMES H. et al., Pyrido[1,2-a]pyrimidinium Salts. Part 1. Synthesis from 2- Aminopyridines and Interconversion with 2-(2-Acylvinylamino) pyridines, J.C.S. Perkin I (1972), 1138-1143.	
	GY	SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, Indian Journal of Experimental Biology, Vol. 34 (1996), pp. 351-355.	
	GZ	SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 1550 (2001), pp. 107-116.	
	HA	SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazino-activity of 6-polymethylenepyrimidines, Eur. J. Med. Chem. (1982), 75-79.	
	HB	SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, Bioorganic & Medicinal Chemistry Letters 12 (2002) pp. 2825-2828.	
	HC	SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolones, Indian Journal of Chemistry, Vol. 14B (1975), 536-540.	
	HD	SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, J. Enzyme Inhibition, Vol. 14 (1999) pp. 259-275.	
	HE	SHISHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion in Vitro and in Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozocin-Induced Rats, Diabetes, Vol. 41 (1992), pp. 982-988.	
	HF	SINYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Heterylmercaptoquinazoline, Translated from Khimiko-farmatsevticheskii Zhurnal, Vol. 20, No. 2, pp 168-171 (1986), pp. 103-105.	
	HG	SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, Journal of Clinical Investigation, Vol. 46, No.5 (1967) pp. 778-785.	
	HH	SRIVASTAVA, P.P. et al., Efficacy of Centpiperalone in Combination With Biguanide & Sulfonylurea, Indian Journal of Experimental Biology, Vol. 21 (1983), pp. 390-392.	
	HI	TANAKA, KEIJI et al, Vanadate Inhibits the ATP-Dependant Degradation of Proteins in Reticulocytes Without Affecting Ubiquitin Conjugation, The Journal of Biological Chemistry, Vol. 259, No. 4 (1983), 2803-2809.	
	HJ	VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, Annual Reports in Chemistry 36 (2001), 191-200.	
✓	HK	VILLHAUER, EDWIN B. et al., 1-[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(5)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, J. Med. Chem. 46 (2003), pp. 2774-2789.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/809,638
				Filing Date	March 24, 2004
				First Named Inventor	Jun Feng
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	10	of	10	Attorney Docket Number	SYR-DPP-IV-5004-C3


✓	HL	WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2689-94.	
	HM	WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes, Current Opinion in Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420.	
	HN	YASUDA, NOBUYUKI et al. Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784.	
	HO	YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rats, Diabetes Research and Clinical Practice 43 (1999), pp. 9-19.	
	HP	ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725.	
✓	HQ	ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-56.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Sheet 1 of 2

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	SYR-DPP-IV-5004-C3

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH	AA	US1988/578344	12-25-1988	Kuroki et al.	
	AB	US2002/0169159	11-14-2002	Medina et al.	
	AC	US2003/0089234	4-10-2003	Medina et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KH	AD	BR 699812	11-29-1950	The Distillers Company Limited		
	AE	53005180 A	01-18-1978	Sumitomo Chem		
	AF	EP 1136482 A1	09-26-2001	Sanofi-Synthelabo		
	AG	WO 01/86295 A2	12-20-2001	Novartis AG		
	AH	WO 02/02560 A2	01-10-2002	Novo Nordisk		
	AI	WO 03/000181 A2	01-03-2003	Merck & Co., Inc.		
	AJ	WO 03/007888 A2	01-30-2003	Adipogenix, Inc.		
	AK	WO 03/027080 A1	04-03-2003	Mitsubishi Pharma		
	AL	WO 03/037888 A1	05-08-2003	Mitsubishi Pharma		
	AM	WO 03/076418 A1	09-18-2003	X-Ceptor Therapeutics, Inc.		
	AN	WO 04/062613 A2	07-29-2004	Bristol-Myers Squibb		
	AO	WO 04/085408 A1	10-07-2004	Mitsubishi Pharma		


Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	SYR-DPP-IV-5004-C3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FK	AP	DEY, PARAMITA D., et al., Regioselective [4+2] Cycloaddition versus Nucleophilic Reactions of N-Arylamino Substituted 1,3-Diaza-1,3-Butadienes with Ketenes: Synthesis of Pyrimidinone and Fused Pyrimidine Derivatives. Part II. Tetrahedron, Vol. 53, No. 40, pp. 13829-13840, 1997.	
	AQ	JAKUBKIENE, VIRGINIA, et al., (G-Methyl-2-methylsulfanyl-4-oxo-3,4-dihydro-3-pyrimidinyl)acetic acid and related compounds exhibiting anti-inflammatory activity. Pharmazie 57 (2002) 9, pp. 610-613.	
	AR	JONES, TERENCE R., et al., Azafluorenes Containing Two Bridgehead Nitrogen Atoms. Journal of the Chemical Society, Perkin Transactions 1, No. 12, December 1987, pp. 2585-2592.	
	AS	SHARMA, ARUN K., et al., Tandem sigmatropic shifts in [4 + 2] cycloaddition reactions of 1,3-diazabuta-1,3-dienes with butadienylketene: synthesis of pyrimidinone derivatives. J. Chem. Soc., Perkin Trans. 1, 2002, 774-784.	
	AT	Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310120. Beilstein Registry Number 638238 & Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1, 1988, page 92.	
	AU	Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310119. Beilstein Registry Number 649497 & J. Pharm. Sci. Vol. 80, No. 7, 1991, pp. 705-706.	
	AV	Database CA Online Chemical Abstracts Service, Columbus, OH, US; Troschuetz, Reinhard et al., The reaction of O-functional benzylmalononitriles with N-bisnucleophiles as well as alcoholates. XP-002311761 retrieved from STN Database accession No. 1994:217538 abstract & Archiv Der Pharmazie (Winheim, Germany), 326(11), 865-9 Coden: ARPMA5; ISSN: 0365-6233, 1993.	
	AW	Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310121. Beilstein Registry Number 7289032 & Nucleosides Nucleotides, Vol. 14, No. 3-5, 1995, pp. 653-656.	
	AX	Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310118. Beilstein Registry Number 7643826 & KHIM. Geterotsikl. Soedin., Vol. 32, No. 5, 1996, pp. 703-707.	
	AY	Database Crossfire Beilstein Institut Zur Foerderung Der Chmischen Wissenschaften. XP-002310117. Beilstein Registry Number 8373244 & KHIM. Geterotsikl. Soedin., No. 8, 1998, pp. 1125-1129.	


Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 1 of 1	Attorney Docket Number	SYR-DPP-IV-5004-C3	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. 1	Document Number Number - Kind Code 2 (if known)	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code 3 - Number 4 - Kind Code 5 (if known)					
KH	AA	WO 03/035057 A		05/01/2003	Ferring B.V.		
J	AB	DE 21 50 686 A1		4/19/1973	Badische Anilin & Soda Fabrik AG		
	AC	EP 0 442 473 A		08/21/1991	Takeda Chemical Industries, Ltd.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
KH	AD	WEBER, A.E.: Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes, Journal of Medicinal Chemistry, vol. 47, 2004 pages 4135-4141, XP002329845	
	AE	Patent Abstracts of Japan, vol. 2003, no. 12, Xanthine Derivative, December 5, 2003 & JP 2003 300977 A (Sumitomo Pharmaceut Co Ltd), October 21, 2003, Abstract	
	AF	BOTTA, M., SALADINO, R., LAMBA, D. NICOLETTI, R.: Researches on Antiviral Agents. 31. Synthesis and Transformations of Racemic and Chiral 6-Oxiranyl Pyrimidinones, Tetrahedron, vol. 49, 1993, pages 6053-6070, XP002329846	
	AG	FRAISSE, L., et al. Long-Chained Substituted Uric Acid and 5,6-Diaminouracil Derivatives as Novel Agents against Free Radical Processes: Synthesis and in Vitro Activity, Journal of Medicinal Chemistry, vol. 36, 1993, pages 1456-1473, XP002329847	
	AH	KIM, H.O. et al., Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A ₃ Adenosine Receptors, Journal of Medicinal Chemistry, vol. 37, 1994, pages 3373-3382, XP002329848	

Examiner Signature		Date Considered	10/19/2006
-----------------------	--	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 14

Complete if Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614 1624
Examiner Name	Not Yet Assigned K. Hable
Attorney Docket Number	DPP-IV-5004-C3

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH	AA	US 3,960,949	6/1/1978	Ahrens, Hanns et al.	
	AB	US 4,494,978	1/22/1985	Chan, David C. K.;	
	AC	US 4,935,493	6/19/1990	Bachovchin, William W. et al.	
	AD	US 5,366,862	11/22/1994	Venton, Duane L. et al.	
	AE	US 5,387,512	02/07/1995	Balan, Suresh K. et al.	
	AF	US 5,433,955	7/18/1995	Bredehorst, Reinhard et al.	
	AG	US 5,462,928	10/31/1995	Bachovchin, William W. et al.	
	AH	US 5,543,396	8/6/1996	Powers, James C. et al.	
	AI	US 5,601,986	2/11/1997	Takacs, Laszlo	
	AJ	US 5,614,379	3/25/1997	MacKellar, Warren C.	
	AK	US 5,624,894	4/29/1997	Bodor, Nicholas S.	
	AL	US 5,811,278	09/22/1998	Okamura, Hideki et al.	
	AM	US 5,811,281	09/22/1998	Quaroni, Andrea et al.	
	AN	US 5,814,460	9/29/1998	Venton, Duane L. et al.	
	AO	US 5,885,997	3/23/1999	Lohray, Vidya Bhushan et al.	
	AP	US 5,939,560	8/17/1999	Jenkins, Paul D. et al.	
	AQ	US 5,965,532	10/12/1999	Bachovchin, William W.	
	AR	US 5,985,884	11/16/1999	Lohray, Vidya Bhushan et al.	
	AS	US 6,006,753	12/28/1999	Efendic, Suad	
	AT	US 6,011,155	1/4/2000	Vilhauer, Edwin Bernard	
	AU	US 6,090,786	7/18/2000	Augustyns, Koen Jan Ludovicus et al.	
	AV	US 6,107,317	8/22/2000	Vilhauer, Edwin Bernard	
	AW	US 6,110,949	8/29/2000	Vilhauer, Edwin Bernard	
	AX	US 6,124,305	9/26/2000	Vilhauer, Edwin Bernard	
	AY	US 6,129,911	10/10/2000	Faris, Ronald A.	
	AZ	US 2001/0018210	8/30/2001	Bachovchin, William et al.	
	BA	US 2001/0031780	10/18/2001	Kanstrup, Anders et al.	
	BB	US 2001/0047078	11/29/2001	Chang, Yie-Hwa	
	BC	US 6,172,081	1/9/2001	Damon, Robert	
	BD	US 6,184,020	2/6/2001	Blinkovsky, Alexander et al.	
	BE	US 6,201,132	3/13/2001	Jenkins, Paul D. et al.	
	BF	US 6,214,340	4/10/2001	Takeuchi, Tomio et al.	
	BG	US 6,235,493	5/22/2001	Bissell, Eugene R. et al.	
	BH	US 6,251,391	6/26/2001	Wilkinson, Randall Eugene et al.	

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **14****Complete if Known**

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

BI	US 6,261,794	7/17/2001	Chang, Yie-Hwa	
BJ	US 6,265,551	7/24/2001	Duke-Cohan, Jonathan S. et al.	
BK	US 6,309,868	10/30/2001	Monod, Michel	
BL	US 6,310,069	10/30/2001	Lohray, Vidya Bhushan et al.	
BM	US 6,325,989	12/4/2001	Duke-Cohan, Jonathan S. et al.	
BN	US 2002/0006899	1/17/2002	Pospisilik, Andrew J. et al.	
BO	US 2002/0019411	2/14/2002	Robl, Jeffrey A. et al.	
BP	US 2002/0037829	3/28/2002	Aronson, Peter S. et al.	
BQ	US 2002/0041871	4/11/2002	Brudnak, Mark A.	
BR	US 2002/0061839	5/23/2002	Scharpe, Simon Lodewijk et al.	
BS	US 2002/0071838	6/13/2002	Demuth, Hans-Ulrich et al.	
BT	US 2002/0077340	06/20/2002	Sulsky, Richard et al.	
BU	US 2002/0082292	6/27/2002	Sahoo, Soumya P. et al.	
BV	US 2002/0103242	8/1/2002	Sahoo, Soumya P. et al.	
BW	US 2002/0103384	8/1/2002	Kanstrup, Anders et al.	
BX	US 2002/0110560	8/15/2002	Demuth, Hans-Ulrich et al.	
BY	US 2002/0115843	08/22/2002	Oi, Steve et al.	
BZ	US 2002/0132979	9/19/2002	Chen, Wen-Tien	
CA	US 2002/0147130	10/10/2002	Huber, Brigitte T. et al.	
CB	US 2002/0147157	10/10/2002	Connor, Gregory S.	
CC	US 2002/0155565	10/24/2002	Garin-Chesa, Pilar et al.	
CD	US 2002/016100	02/07/2002	Okabe, Toshiaki et al.	
CE	US 2002/0164759	11/7/2002	Travis, James et al.	
CF	US 2002/0165164	11/7/2002	Demuth, Hans-Ulrich et al.	
CG	US 2002/0183367	12/5/2002	Sulsky, Richard B. et al.	
CH	US 2002/0193390	12/19/2002	Vilhauer, Edwin Bernard	
CI	US 2002/0198205	12/26/2002	Himmelsbach, Frank et al.	
CJ	US 6,335,429	1/1/2002	Cal, Sui Xiong et al.	
CK	US 6,337,069	1/8/2002	Grouzmann, Eric et al.	
CL	US 6,342,611	1/29/2002	Weber, Eckard et al.	
CM	US 6,355,614	3/12/2002	Wallner, Barbara P	
CN	US 6,395,767	5/28/2002	Robl, Jeffrey A. et al.	
CO	US 6,432,969	8/13/2002	Vilhauer, Edwin Bernard	
CP	US 6,447,772	9/10/2002	Houston, Devin B.	
CQ	US 6,458,924	10/1/2002	Knudsen, Liselotte Bjerre et al.	
CR	US 6,485,955	11/26/2002	Huber, Brigitte T. et al.	
CS	US 6,495,544	12/17/2002	Hansen, Jr., Donald W. et al.	
CT	US 2003/0008905	1/9/2003	Demuth, Hans-Ulrich et al.	

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **14****Complete if Known**

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

<input checked="" type="checkbox"/>	CU	US 2003/0027282	2/6/2003	Huber, Brigitte T. et al.	
<input checked="" type="checkbox"/>	CV	US 2003/0040478	2/27/2003	Drucker, Daniel J. et al.	
<input checked="" type="checkbox"/>	CW	US 2003/0045464	3/6/2003	Harmeling, Ronald Norbert et al.	
<input checked="" type="checkbox"/>	CX	US 2003/0055052	3/20/2003	Peters, Stefan et al.	
<input checked="" type="checkbox"/>	CY	US 2003/0060412	3/27/2003	Prouty, Walter Francis et al.	
<input checked="" type="checkbox"/>	CZ	US 2003/0060434	3/27/2003	Nielsen, Loretta et al.	
<input checked="" type="checkbox"/>	DA	US 2003/0087935	5/8/2003	Cheng, Peter T. et al.	
<input checked="" type="checkbox"/>	DB	US 2003/0087950	5/8/2003	DeNanteuil, Guillaume et al.	
<input checked="" type="checkbox"/>	DC	US 2003/0089935	5/15/2003	Fan, Tso-Hung et al.	
<input checked="" type="checkbox"/>	DD	US 2003/0092697	5/15/2003	Cheng, Peter T. et al.	
<input checked="" type="checkbox"/>	DE	US 2003/0096846	5/22/2003	Cheng, Peter T. et al.	
<input checked="" type="checkbox"/>	DF	US 2003/0096857	5/22/2003	Evans, David Michael et al.	
<input checked="" type="checkbox"/>	DG	US 2003/0100563	5/29/2003	Edmondson, Scott D. et al.	
<input checked="" type="checkbox"/>	DH	US 2003/0103968	6/5/2003	Amelsberg, Andree et al.	
<input checked="" type="checkbox"/>	DI	US 2003/0105077	6/5/2003	Kanstrup, Anders Bendtz et al.	
<input checked="" type="checkbox"/>	DJ	US 2003/0119736	6/26/2003	Demuth, Hans-Ulrich et al.	
<input checked="" type="checkbox"/>	DK	US 2003/0119738	6/26/2003	Niestroj, Andre et al.	
<input checked="" type="checkbox"/>	DL	US 2003/0125304	7/3/2003	Demuth, Hans-Ulrich et al.	
<input checked="" type="checkbox"/>	DM	US 2003/0130281	7/10/2003	Boehringer, Markus et al.	
<input checked="" type="checkbox"/>	DN	US 2003/0130306	7/10/2003	Devasthale, Pratik et al.	
<input checked="" type="checkbox"/>	DO	US 2003/0139429	7/24/2003	Cohen, David Saul et al.	
<input checked="" type="checkbox"/>	DP	US 2003/0139434	7/24/2003	Balkan, Bork et al.	
<input checked="" type="checkbox"/>	DQ	US 2003/0144206	7/31/2003	Knudsen, Lotte Bjerre et al.	
<input checked="" type="checkbox"/>	DR	US 2003/0149071	8/7/2003	Gobbi, Luca Claudio et al.	
<input checked="" type="checkbox"/>	DS	US 2003/0166662	9/4/2003	Fryburg, David Albert et al.	
<input checked="" type="checkbox"/>	DT	US 2003/0166690	9/4/2003	Ebdrup, Soren et al.	
<input checked="" type="checkbox"/>	DU	US 2003/0171358	9/11/2003	Jeppesen, Lone et al.	
<input checked="" type="checkbox"/>	DV	US 2003/0171411	9/11/2003	Kodra, Janos Tibor et al.	
<input checked="" type="checkbox"/>	DW	US 2003/0181497	9/25/2003	Chen, Ping et al.	
<input checked="" type="checkbox"/>	DX	US 2003/0186963	10/2/2003	Dorwald, Florencio Zaragoza et al.	
<input checked="" type="checkbox"/>	DY	US 2003/0187254	10/2/2003	Perry, David A. et al.	
<input checked="" type="checkbox"/>	DZ	US 2003/0191112	10/9/2003	Dorwald, Florencio Zaragoza et al.	
<input checked="" type="checkbox"/>	EA	US 2003/0195188	10/16/2003	Boehringer, Markus et al.	
<input checked="" type="checkbox"/>	EB	US 2003/0195190	10/16/2003	Peschke, Bernd et al.	
<input checked="" type="checkbox"/>	EC	US 2003/0199528	10/23/2003	Kanstrup, Anders B. et al.	
<input checked="" type="checkbox"/>	ED	US 2003/0199563	10/23/2003	Robl, Jeffrey A. et al.	
<input checked="" type="checkbox"/>	EE	US 2003/0203946	10/30/2003	Behrens, Carsten et al.	
<input checked="" type="checkbox"/>	EF	US 2003/0216382	11/20/2003	Boehringer, Markus et al.	

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

14

Complete if Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

✓	EG	US 2003/0216450	11/20/2003	Evans, David Michael et al.	
	EH	US 2003/0220345	11/27/2003	Hamby, James Marino et al.	
	EI	US 2003/0225102	12/4/2003	Sankaranarayanan, Alangudi	
	EJ	US 2003/0232761	12/18/2003	Hinke, Simon A. et al.	
	EK	US 6,521,644	2/18/2003	Broqua, Pierre	
	EL	US 6,528,486	3/4/2003	Larsen, Bjarne Due et al.	
	EM	US 6,545,170	4/8/2003	Pitzels, Barnett S et al.	
	EN	US 6,548,529	4/15/2003	Robt, Jeffrey A. et al.	
	EO	US 6,555,519	4/29/2003	Washburn, William N.	
	EP	US 6,555,521	4/29/2003	Hermeling, Ronald Norbert et al.	
	EQ	US 6,559,188	5/6/2003	Gatlin, Marjorie Regan et al.	
	ER	US 6,573,096	6/3/2003	Chen, Wen-Tien	
	ES	US 6,573,287	6/3/2003	Sulsky, Richard B. et al.	
	ET	US 6,586,198	7/1/2003	Brown, Nancy J.	
	EU	US 6,608,038	8/19/2003	Caplan, Shari L. et al.	
	EV	US 6,617,340	9/9/2003	Vilhauer, Edwin Bernard	
	EW	US 6,620,821	9/16/2003	Robt, Jeffrey A.	
	EX	US 6,627,636	9/30/2003	Robt, Jeffrey A.	
	EY	US 6,645,995	11/11/2003	Kanstrup, Anders et al.	
	EZ	US2004/0002495	1/1/2004	Sher, Philip et al.	
	FA	US2004/0002609	1/1/2004	Hulin, Bernard	
	FB	US2004/0006062	1/8/2004	Smallheer, Joanne M. et al.	
	FC	US2004/0009972	1/15/2004	Ding, Charles Z. et al.	
	FD	US2004/0009998	1/15/2004	Dhar, T. G. Murali et al.	
	FE	US2004/0034014	2/19/2004	Kanstrup, Anders Bendtz et al.	
	FF	US2004/0053369	3/18/2004	Abbott, Catherine Anne et al.	
	FG	US2004/0063935	4/1/2004	Yasuda, Kosuke	
	FH	US2004/0072874	4/15/2004	Sato, Nagaaki et al.	
	FI	US2004/0072892	4/15/2004	Fukushima, Hiroshi et al.	
	FJ	US2004/0077645	4/22/2004	Himmelsbach, Frank et al.	
	FK	US2004/0082497	4/29/2004	Evans, David Michael et al.	
	FL	US2004/0082607	04/29/2004	Oi, Satou et al.	
	FM	US2004/0087587	5/6/2004	Himmelsbach, Frank et al.	
	FN	US2004/0092478	5/13/2004	Rothermel, John D. et al.	
	FO	US2004/0097510	5/20/2004	Himmelsbach, Frank et al.	
	FP	US2004/0106655	6/3/2004	Kitajima, Hiroshi et al.	
	FQ	US2004/0106656	6/3/2004	Ashton, Wallace T. et al.	
✓	FR	US2004/0106802	6/3/2004	Sankaranarayanan, Alangudi et al.	

Examiner
Signature

Date

Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **5** of **14****Complete if Known**

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

✓	FS	US2004/0110817	6/10/2004	Hulin, Bernard	
	FT	US2004/0116328	6/17/2004	Yoshikawa, Seiji et al.	
	FU	US2004/0132713	7/8/2004	Hulin, Bernard et al.	
	FV	US2004/0138148	7/15/2004	Fushimi, Nobuhiko et al.	
	FW	US2004/0138214	7/15/2004	Himmelsbach, Frank et al.	
	FX	US2004/0138215	7/15/2004	Eckhardt, Matthias et al.	
	FY	US2004/0147434	7/29/2004	Ansorge, Siegfried et al.	
	FZ	US2004/0152192	8/5/2004	Bachovchin, William et al.	
	GA	US2004/0152745	8/5/2004	Jackson, Paul et al.	
	GB	US2004/0166125	8/26/2004	Himmelsbach, Frank et al.	
	GC	US2004/0167133	8/26/2004	Edmondson, Scott D. et al.	
	GD	US2004/0167341	8/26/2004	Haffner, Curt Dale et al.	
	GE	US2004/0171104	9/2/2004	Blinkovsky, Alexander et al.	
	GF	US2004/0171848	9/2/2004	Haffner, Curt Dale et al.	
	GG	US2004/0176406	9/9/2004	Gobbi, Luca Claudio et al.	
	GH	US2004/0176428	9/9/2004	Edmondson, Scott D et al.	
	GI	US2004/0180925	9/16/2004	Matsuno, Kenji et al.	
	GJ	US2004/0186153	9/23/2004	Yasuda, Nobuyuki et al.	
	GK	US2004/0198786	10/7/2004	Gretzke, Dirk et al.	
	GL	US2004/0209891	10/21/2004	Broqua, Pierre et al.	
	GM	US2004/0229820	11/18/2004	Bachovchin, William W. et al.	
	GN	US2004/0229848	11/18/2004	Demuth, Hans-Ulrich et al.	
	GO	US2004/0236102	11/25/2004	Brockunier, Linda et al.	
	GP	US2004/0242566	12/2/2004	Feng, Jun et al.	
	GQ	US2004/0242568	12/2/2004	Feng, Jun et al.	
	GR	US2004/0242636	12/2/2004	Haffner, Curt Dale et al.	
	GS	US2004/0242898	12/2/2004	Hulin, Bernard et al.	
	GT	US2004/0254167	12/16/2004	Biftu, Tesfaye et al.	
	GU	US2004/0254226	12/16/2004	Feng, Jun et al.	
	GV	US2004/0259843	12/23/2004	Madar, David J. et al.	
	GW	US2004/0259870	12/23/2004	Feng, Jun et al.	
	GX	US2004/0259883	12/23/2004	Sakashita, Hiroshi et al.	
	GY	US2004/0259902	12/23/2004	Boehringer, Markus et al.	
	GZ	US2004/0259903	12/23/2004	Boehringer, Markus et al.	
	HA	US2004/0259919	12/23/2004	Magnin, David R. et al.	
	HB	US 6,673,815	1/6/2004	Devasthale, Pratik et al.	
	HC	US 6,673,829	1/6/2004	Dorwald, Florencio Zaragoza et al.	
✓	HD	US 6,686,337	2/3/2004	Connor, Gregory S.	

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 14

Complete if Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

KH	HE	US 6,699,871	3/2/2004	Edmondson, Scott D. et al.	
	HF	US 6,706,742	3/16/2004	De Nanteuil, Guillaume et al.	
	HG	US 6,710,040	3/23/2004	Hulin, Bernard et al.	
	HH	US 6,716,843	4/6/2004	De Nanteuil, Guillaume et al.	
	HI	US 6,727,261	4/27/2004	Gobbi, Luca Claudio et al.	
	HJ	US 6,727,271	4/27/2004	Cheng, Peter T. et al.	
	HK	US 6,800,650	10/5/2004	Boehringer, Markus et al.	
	HL	US 6,803,357	10/12/2004	Bachovchin, William A. et al.	
	HM	US 6,825,169	11/30/2004	Bachovchin, William W. et al.	
	HN	US2005/0014732	1/20/2005	Gulve, Eric Arthur et al.	
	HO	US2005/0014946	1/20/2005	Demuth, Hans-Ulrich et al.	
	HP	US2005/0020574	1/27/2005	Hauel, Norbert et al.	
	HQ	US2005/0026921	2/3/2005	Eckhardt, Matthias et al.	
	HR	US2005/0032804	2/10/2005	Cypes, Stephen Howard et al.	
	HS	US2005/0038020	2/17/2005	Hamann, Lawrence G. et al.	
	HT	US2005/0043292	2/24/2005	Parker, Janice C. et al.	
	HU	US2005/0043299	2/24/2005	Evans, David M. et al.	
	HV	US2005/0058635	3/17/2005	Demuth, Hans-Ulrich et al.	
	HW	US 6,861,440	3/1/2005	Boehringer, Markus et al.	
	HX	US 6,867,205	3/15/2005	Boehringer, Markus et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*		Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)				
KH	HY	DE 2361551A1	6/19/1975	BASF AG		
	HZ	DE 2500024A1	7/8/1976	BASF AG,		
	IA	EP 0505893	9/30/1992	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IB	EP 0547514	6/23/1993	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IC	EP 0574846	12/22/1993	MERCK PATENT GmbH		

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

14

Complete if Known

Application Number

10/809,638

Filing Date

March 24, 2004

First Named Inventor

Jun FENG

Group Art Unit

1614

Examiner Name

Not Yet Assigned

Attorney Docket Number

DPP-IV-5004-C3

141	ID	EP 0657452	6/14/1995	MERCK PATENT GmbH		
	IE	EP 0702013	3/20/1996	MERCK PATENT GmbH		
	IF	GB 1441665A	7/7/1976	COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION		
	IG	WO 91/11457	8/8/1991	BUCKLEY, Douglas, I. Et al.		
	IH	WO 95/15309	6/8/1995	FERRING B.V.		
	II	WO 95/29691	11/9/1995	GEORGIA TECH RESEARCH CORPORATION		
	IJ	WO 96/02667	2/1/1996	AMGEN INC.		
	IK	WO 98/18763	5/7/1998	TANABE SEIYAKU CO., LTD.		
	IL	WO 98/19998	5/14/1998	NOVARTIS AG		
	IM	WO 98/50046	11/12/1998	TRUSTEES OF TUFTS COLLEGE		
	IN	WO 98/51803	11/19/1998	NOVO NORDISK BIOTECH, INC.		
	IO	WO 99/02705	1/21/1999	SOCIETE DES PRODUITS NESTLE S.A.		
	IP	WO 99/17799	4/15/1999	TRUSTEES OF TUFTS COLLEGE ET AL.		
	IQ	WO 99/18856	4/22/1999	CYTOVIA, INC.		
	IR	WO 99/28474	6/10/1999	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES		
	IS	WO 99/46272	9/16/1999	FONDATECH BENELUX N.V.		
	IT	WO 99/47152	9/23/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH		
	IU	WO 99/62914	12/9/1999	POINT THERAPEUTICS, INC.		
	IV	WO 00/10549	3/2/2000	POINT THERAPEUTICS, INC.		
	IW	WO 00/20416	4/13/2000	GANTE, Helga		
	IX	WO 00/40583	7/13/2000	MERCK PATENT GMBH		
	IY	WO 00/43366	7/27/2000	KIRIN BEER KABUSHIKI KAISHA		
	IZ	WO 00/56296	9/28/2000	FERRING BV		
	JA	WO 00/56297	9/28/2000	FERRING B.V.		
	JB	WO 01/16301	3/8/2001	TUFTS UNIVERSITY		

Examiner
Signature*[Handwritten Signature]*Date
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

14

Complete if Known

Application Number

10/809,638

Filing Date

March 24, 2004

First Named Inventor

Jun FENG

Group Art Unit

1614

Examiner Name

Not Yet Assigned

Attorney Docket Number

DPP-IV-5004-C3

KN	JC	WO 01/19866	3/22/2001	THE UNIVERSITY OF SYDNEY		
	JD	WO 01/40180	6/7/2001	FERRING BV		
	JE	WO 01/55105	8/2/2001	NOVO NORDISK A/S		
	JF	WO 01/62266	8/30/2001	NOVO NORDISK A/S		
	JG	WO 01/68603	9/20/2001	BRISTOL-MYERS SQUIBB CO.		
	JH	WO 01/72290	10/4/2001	PROBIODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH		
	JI	WO 01/74299	10/11/2001	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK		
	JJ	WO 01/79206	10/25/2001	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED		
	JK	WO 01/81304	11/1/2001	FERRING BV		
	JL	WO 01/81337	11/1/2001	FERRING B.V.		
	JM	WO 01/89569	11/29/2001	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH IMTM		
	JN	WO 01/94597	12/13/2001	PROZYMEX A/S		
	JO	WO 02/04610	1/17/2002	BAYER AKTIENGESELLSCHAFT		
	JP	WO 02/051836	7/4/2002	KYOWA HAKKO KOGYO CO., LTD		
	JQ	WO 02/053170	7/11/2002	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM)		
	JR	WO 02/059301	8/1/2002	K.U. LEUVEN RESEARCH AND DEVELOPMENT		
	JS	WO 02/059343	8/1/2002	VANDERBILT UNIVERSITY		
	JT	WO 02/062764	8/15/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	JU	WO 02/066627	8/29/2002	BAYER AKTIENGESELLSCHAFT		
	JV	WO 02/068420	9/6/2002	BOEHRINGER INGELHEIM PHARMA KG		
	JW	WO 02/076450	10/3/2002	MERCK & CO., INC.		
	JX	WO 02/083128	10/24/2002	BRISTOL-MYERS SQUIBB COMPANY		
	JY	WO 02/08931	1/31/2002	TEN SQUARE		
	JZ	WO 02/092127	11/21/2002	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
	KA	WO 02/096357	12/5/2002	BRISTOL-MYERS SQUIBB COMPANY		

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9

of

14

Complete If Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

KN	KB	WO 02/14271	2/21/2002	WELFIDE CORPORATION		
	KC	WO 02/20804	3/14/2002	PROZYMEX A/S		
	KD	WO 02/26703	4/4/2002	PROLIFIX LIMITED		
	KE	WO 02/28742	4/11/2002	JOHANSSON, Thomas		
	KF	WO 02/30890	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KG	WO 02/30891	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KH	WO 02/31134	4/18/2002	FERRING BV		
	KI	WO 02/34900	5/2/2002	THE UNIVERSITY OF SYDNEY		
	KJ	WO 02/38541	5/16/2002	TAISHO PHARMACEUTICAL CO., LTD.		
	KK	WO 02/38742	5/16/2002	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.		
	KL	WO 03/000180	1/3/2003	MERCK & CO., INC.		
	KM	WO 03/000250	1/3/2003	FERRING BV		
	KN	WO 03/002530	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KO	WO 03/002531	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KP	WO 03/002553	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KQ	WO 03/004496	1/16/2003	NOVO NORDISK A/S		
	KR	WO 03/004498	1/16/2003	MERCK & CO., INC.		
	KS	WO 03/010197	2/6/2003	GENSET S.A.		
	KT	WO 03/010314	2/6/2003	GENSET S.A.		
	KU	WO 03/011807	2/13/2003	NOVO NORDISK A/S		
	KV	WO 03/011814	2/13/2003	NOVO NORDISK A/S		
	KW	WO 03/011834	2/13/2003	NOVO NORDISK A/S		
	KX	WO 03/011892	2/13/2003	THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	KY	WO 03/014318	2/20/2003	GENZYME CORPORATION		
	KZ	WO 03/015775	2/27/2003	PROBIODRUG AG		
	LA	WO 03/017936	3/6/2003	YALE UNIVERSITY		
	LB	WO 03/024942	3/27/2003	MITSUBISHI PHARMA CORPORATION		

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 14

Complete if Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

✓	LC	WO 03/024965	3/27/2003	NOVO NORDISK A/S		
	LD	WO 03/035067	5/1/2003	FERRING B.V.		
	LE	WO 03/037327	5/8/2003	F. HOFFMANN-LA-ROCHE AG		
	LF	WO 03/038123	5/8/2003	NOVARTIS AG		
	LG	WO 03/040114	5/15/2003	BRISTOL-MYERS SQUIBB COMPANY		
	LH	WO 03/051848	6/26/2003	FERRING BV		
	LI	WO 03/053330	3/7/2003	ASTRAZENECA AB		
	LJ	WO 03/055881	7/10/2003	F. HOFFMANN-LA ROCHE AG		
	LK	WO 03/057144	7/17/2003	GUILFORD PHARMACEUTICALS		
	LL	WO 03/057666	7/17/2003	GUILFORD PHARMACEUTICALS		
	LM	WO 03/065983	8/14/2003	MERCK & CO., INC.		
	LN	WO 03/068748	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LO	WO 03/068757	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LP	WO 03/072197	9/4/2003	PFIZER PRODUCTS INC.		
	LQ	WO 03/074500	9/12/2003	SANOFI-SYNTHELABO		
	LR	WO 03/076393	9/18/2003	NOVARTIS AG		
	LS	WO 03/077935	9/25/2003	IMTM INSTITUT FUR MEDIZINTECHNOLOGIE MAGDEBURG GMBH,		
	LT	WO 03/080070	10/2/2003	NOVARTIS AG		
	LU	WO 03/080633	10/2/2003	NIPPON KAYAKU KABUSHIKI KAISHA		
	LV	WO 03/082817	10/9/2003	MERCK & CO., INC.		
	LW	WO 03/082859	10/9/2003	NOVARTIS AG		
	LX	WO 03/084940	10/16/2003	SANKARANARAYANAN, Alangudi		
	LY	WO 03/101449	12/11/2003	PFIZER PRODUCTS INC.		
	LZ	WO 03/101958	12/11/2003	PFIZER PRODUCTS INC.		
	MA	WO 03/104207	12/18/2003	MERCK & CO., INC.		
	MB	WO 03/104208	12/18/2003	MERCK & CO., INC.		
	MC	WO 03/104229	12/18/2003	EISAI CO., LTD.		

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 14

Complete if Known

Application Number	10/809,638
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	DPP-IV-5004-C3

KK	MD	WO 03/106456	12/24/2003	SANOFI-SYNTHELABO		
	ME	WO 04/002535	1/8/2004	HORMOS MEDICAL CORPORATION		
	MF	WO 04/002986	1/8/2004	BANYU PHARMACEUTICAL CO., LTD.		
	MG	WO 04/004655	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MH	WO 04/004661	1/15/2004	POINT THERAPEUTICS, INC.		
	MI	WO 04/004665	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MJ	WO 04/007446	1/22/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	MK	WO 04/007468	1/22/2004	MERCK & CO., INC.		
	ML	WO 04/011640	2/5/2004	TANABE SEIYAKU CO., LTD.		
	MM	WO 04/014860	2/19/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	MN	WO 04/018467	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MO	WO 04/018468	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MP	WO 04/018469	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	MQ	WO 04/020407	3/11/2004	TAISHO PHARMACEUTICAL CO., LTD.		
	MR	WO 04/024184	3/25/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	MS	WO 04/026822	4/1/2004	ABBOTT LABORATORIES		
	MT	WO 04/028524	4/8/2004	EISAI CO., LTD.		
	MU	WO 04/031175	4/15/2004	BANYU PHARMACEUTICAL CO., LTD.		
	MV	WO 04/032836	4/22/2004	MERCK & CO., INC.		
	MW	WO 04/032861	4/22/2004	BRISTOL-MYERS SQUIBB COMPANY		
	MX	WO 04/033455	4/22/2004	NOVO NORDISK A/S		
	MY	WO 04/037169	5/6/2004	MERCK & CO., INC.		
	MZ	WO 04/037181	5/6/2004	BRISTOL-MYERS SQUIBB COMPANY		
	NA	WO 04/041795	5/21/2004	GUILFORD PHARMACEUTICALS INC.		
	NB	WO 04/043940	5/27/2004	MERCK & CO., INC.		
	NC	WO 04/046106	6/3/2004	PFIZER PRODUCTS INC.,		

Examiner
SignatureDate
Considered

10/19/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/809,638
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	DPP-IV-5004-C3
Sheet	12	of	14

KH	ND	WO 04/048352	6/10/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	NE	WO 04/050022	6/17/2004	MERCK & CO., INC.		
	NF	WO 04/050656	6/17/2004	EISAI CO., LTD.		
	NG	WO 04/050658	6/17/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG		
	NH	WO 04/052850	8/24/2004	BRISTOL-MYERS SQUIBB COMPANY		
	NI	WO 04/058266	7/15/2004	MERCK & CO., INC.		
	NJ	WO 04/064778	8/5/2004	MERCK & CO. INC.		
	NK	WO 04/067509	8/12/2004	SANWA KAGAKU KENKYUSHO CO., LTD.		
	NL	WO 04/069162	8/19/2004	MERCK & CO., INC.		
	NM	WO 04/071454	8/26/2004	GUILFORD PHARMACEUTICALS INC.		
	NN	WO 04/075815	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NO	WO 04/075891	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NP	WO 04/076401	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH		
	NQ	WO 04/076433	9/10/2004	AIC		
	NR	WO 04/076434	9/10/2004	AIC		
	NS	WO 04/078777	9/16/2004	BIOREXIS PHARMACEUTICAL CORPORATION		
	NT	WO 04/080958	9/23/2004	MERCK & CO. INC.		
	NU	WO 04/083212	9/30/2004	MERCK & CO., INC.		
	NV	WO 04/085661	10/7/2004	MERCK & CO., INC.		
	NW	WO 04/087053	10/14/2004	SYRRX, INC.		
	NX	WO 04/087650	10/14/2004	MERCK & CO. INC.		
	NY	WO 04/087880	10/14/2004	BAYER PHARMACEUTICALS CORPORATION		
	NZ	WO 04/089382	10/21/2004	NOVO NORDISK A/S		
	OA	WO 04/096806	11/11/2004	SUMITOMO PHARMACEUTICALS CO. LTD.		
	OB	WO 04/098825	11/18/2004	PROBIODRUG AG		
	OC	WO 04/099134	11/18/2004	PROSIDION LTD.		
	OD	WO 04/099185	11/18/2004	FUJISAWA PHARMACEUTICAL CO. LTD.		
	OE	WO 04/101514	11/25/2004	TAISHO PHARMACEUTICAL CO., LTD.		
	OF	WO 04/103276	12/2/2004	MERCK & CO., INC.		
	OG	WO 04/103993	12/2/2004	SYRRX, INC.		

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	DPP-IV-5004-C3
Sheet	13	of	14

KH	OH	WO 04/110436	12/23/2004	MERCK & CO., INC.		
	OI	WO 04/111041	12/23/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	OJ	WO 04/111051	12/23/2004	BOEHRINGER INGELHEIM INTERNATIONAL GMBH		
	OK	WO 04/112701	12/29/2004	MERCK & CO., INC.		
	OL	WO 05/000846	1/8/2005	F.HOFFMANN-LA ROCHE AG		
	OM	WO 05/003135	1/13/2005	MERCK & CO., INC.		
	ON	WO 05/011581	2/10/2005	MERCK & CO., INC.		
	OO	WO 05/012249	2/10/2005	BRISTOL-MYERS SQUIBB COMPANY		
	OP	WO 05/019168	3/3/2005	PFIZER PRODUCTS INC.		
	OQ	WO 2005/016911	2/24/2005	Symx, Inc.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
KH	OR	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCL.CHEM., Vol. 305, 1972, pages 724-730.	
	OS	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J.ORG.CHEM., Vol. 43, 1978, pages 4069-4074.	
	OT	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 386682 & J.CHEM.SOC., 1952, pages 4985-4990.	
	OU	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389575 & CHEM.BER., Vol. 88, 1968, pages 106-109.	
	OV	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 108-109.	
	OW	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689.	
	OX	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448669 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689.	
	OY	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J.CHEM.SOC.PERKIN TRANS.1, 1980, pages 1370-1380.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet 14 of 14	Attorney Docket Number	DPP-IV-5004-C3	

KH	OZ	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1166-1168.	
	PA	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6219070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324.	
	PB	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392448, J.HETEROCYCL.CHEM., Vol. 8, 1971, pages 367-371.	
	PC	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J. PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151.	
	PD	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185.	
	PE	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335063. Database Accession no. 1525341 & J. HETEROCYCL.CHEM., Vol. 12, 1975, pages 683-687.	
	PF	GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-636, XP000889664 compound 1	
	PG	Kesarwani, A. P. et al.: Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581.	
	PH	Rauchman, B.S. et al. "2,4-Diamino-5-benzylpyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP002335048 Scheme II	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/19/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10809638
Filing Date	2004-03-24
First Named Inventor	Jun FENG
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	DPP4-5004-C3

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS

[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
KU	1	EP 900568 A2	EP		1999-10-03	Chenard et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

Handwritten signature

10/19/2006


**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10809638
Filing Date		2004-03-24
First Named Inventor	Jun FENG	
Art Unit	1624	
Examiner Name	Kahsay Habte	
Attorney Docket Number	DPP4-5004-C3	

KN	1	Chenard et al. J. Med Chem. 2001, 44, 1710-1717	<input type="checkbox"/>
I	2	An abstract of Pattanaik et al. Indian Journal of Chemistry, Section B; Organic Chemistry including Medicinal Chemistry (1998), 37B (12), 1304-1306 from STN CAS online search printout (3 pages).	<input type="checkbox"/>
I	3	Abstract of EP 900568 A2 from STN CAS online search printout (3 pages).	<input type="checkbox"/>
I	4	Kozhevnikov et al. Tr. Perm. Sel.-Khoz. Inst. (1971), No. 79, 66-72 From ref. Zh., Khim. 1972, Abstr. No. 9Zh404 Journal (English Abstract attached).	<input type="checkbox"/>
↓	5	Somasekhara et al. Indian Journal of Pharmacey (1972), 34(5), 121-2.	<input type="checkbox"/>


If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	10/19/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
Sheet 1 of 2	Attorney Docket Number	DPP4-5004-C3	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
KH	AA	US 3,544,570	12-1-1970	Helmut Timmler et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KH	AB	GB 1464248 A	02-09-1977	Imperial Chem Ind Ltd		
	AC	DE 2801289 A1	05-03-1979	Hoechst AG		
	AD	WO 02/09718 A	02-07-2002	The Procter & Gamble Company		
	AE	WO 03/099286	12-04-2003	Bristol-Myers Squibb Co.		
	AF	DE 10256264 A	08-24-2004	Boehringer Ingelheim Pharma GMBH & Co. Kg		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KH	AG	Dumas, Donald J. "Total synthesis of peramine" Journal of Organic Chemistry, American Chemical Society, Easton, US, Vol. 5, 1988, pages 4650-4653, XP002087391.	
	AH	Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US; 1991, Bahaji E-H et al.: "Studies on Immunostimulating Derivatives Synthesis of Some Pyrrolo-1 2-C-Pyrimidines" XP002392081. Database accession no. PREV199192140000 abstract.	
	AI	Database Beilstein [online] Beilstein Crossfire Institut Zur Forderung Der Chemischen Wissenschaften, DE; 1991, XP002392082. Database Accession No. BRN 5340228 abstract.	
	AJ	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; Citation No. 5593878 1991, XP00239083.	
	AK	Database CA [online] Chemical Abstract service, Columbus, Ohio, US; Reg No 102482-94-0 Liu, Gang: "Fungal endophyte-epichloe and its secondary metabolites" XP002392084. Database Accession No. 2004:340837 abstract.	

Examiner Signature		Date Considered	10/19/2006
--------------------	--	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809,638
		Filing Date	March 24, 2004
		First Named Inventor	Jun FENG
		Group Art Unit	1624
		Examiner Name	Kahsay Habte
		Attorney Docket Number	DPP4-5004-C3
Sheet	2	of	2

KH	AL	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1924, XP002392085. Database Accession No. BRN 3789088 abstract.	
	AM	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1989 XP002392088. Database Accession No. BRN 5951213 abstract.	
	AN	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1960 XP002392087. Database Accession No. BRN 609897 abstract.	
	AO	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften, DE; 1993 XP002392088. Database Accession No. BRN 6139401 abstract.	
	AP	Database Beilstein [online] Beilstein Crossfire Institut Zur Foerderung Der Chemischen Wissenschaften DE; 1974 XP002392089. Database Accession No. BRN 514343 abstract.	
	AQ	Akahoshi, F. et al.: "Synthesis and pharmacological activity of triazolo[1,5-a]triazine derivatives inhibiting eosinophilia." Journal of Medicinal Chemistry, Vol. 41, no. 18, (1998-07-30), pages 2985-2993, XP002390903	
	AR	Wang, F. et al.: "A novel Synthesis of Aryl[1,2-a]pyrazine Derivatives" Molecules, Molecular Diversity Preservation International, BASEL, CH, Vol. 9, May 2004 (2004-05), pages 574-582, XP002390904.	
	AS	Kotra, L. P. et al.: "4-Azido-2-pyrimidone Nucleosides and Related Chemistry" Journal of Organic Chemistry, American Chemical Society, Easton, US, Vol. 62, 1997, pages 7267-7271, XP002390905.	
	AT	Tam, S. Y-K, et al.: "Nucleosides 112. Synthesis of Some New Pyrazolo-1 5-A-1 3 5-Triazines and Their C Nucleosides" Journal of Organic Chemistry, Vol. 44, No. 25, 1979, pages 4547-4553, XP002390906.	
	AU	Molina, P. et al.: "Iminophosphorane-mediated annulation of 1,3,5-triazine to benzimidazole: Synthesis of 1,3,5-triazino[1,2-a]benzimidazoles" Synthesis 1992 Germany, No. 3, 1992- pages 297-302, XP002390907.	
	AV	Kobe, J. et al.: "The synthesis of s-triazolo[4.3-a]1,3,5-triazines" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 26, July 1970 (1970-07), pages 3357-3368, XP002390908.	
	AW	Buysens, K. J. et al.: "Synthesis of New Pyrrolo[3,4-b]- and [3,4-c]pyridin(on)es and related 1,7-Naphthyridinones and 2,7-naphthyridines via intramolecular diels-alder reactions of 2(1H)-pyrazinones" Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 52, no. 27, (1996-07-01), pages 9161-9178, XP004104003.	
	AX	Abdel-Rahman, R. M.: "Synthesis of some new fluorine bearing trisubstituted 3-thioxo-1, 2, 4-triazin-5-ones as potential anticancer agents: Farmaco, Edizione Scientifica, Societa Chimica Italiana, Pavia, IT, Vol. 47, No. 3 (1992-03), pages 319-326, XP008000322.	
	AY	Borell, J. I. et al.: "Synthesis, structure and cytotoxicity evaluation of palladium(II) complexes of 4-amino-3-hydrazino-1,2,4-triazin-5(4H)-ones and 4-amino-3-(n-methylhydrazino)-1,2,4-triazin-5(4H)-ones" Anal. De Quimica, Vol. 81, no. 3/4, 1995, pages 243-252, XP008000323.	

Examiner Signature		Date Considered	10/19/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10809638	
	Filing Date		2004-03-24	
	First Named Inventor		Jun Feng	
	Art Unit		1624	
	Examiner Name		Kahsay Hable	
	Attorney Docket Number		DPP4-5004-C3	

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ;	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
KN	1	WO 01/23364 A1	WO		2001-04-05	MERCK PATENT GMBH		<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

At my Pa

10/19/2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10809638
Filing Date	2004-03-24
First Named Inventor	Jun Feng
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	DPP4-5004-C3

KN	1	STN Printout, Barnickel et al. Abstract of WO 01/23364 A1.	<input type="checkbox"/>
----	---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	10/19/2006
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.